{
  "abstract": "NHS watchdogs will re-evaluate their decision not to fund two new Alzheimer’s treatments on the health service after appeals from the drugs’ manufacturers.",
  "authors": [
    {
      "affiliations": [
        "The BMJ"
      ],
      "name": "Gareth Iacobucci"
    }
  ],
  "title": "Alzheimer’s drugs: Lecanemab and donanemab to be reconsidered for NHS after appeal",
  "uid": "1e077c06-c7df-5bf2-b7cf-96dd56c249e9"
}